---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-002153"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T10:24:15.526166+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics CEO J. Scott Wolchko retires; Bahram Valamehr appointed successor; advisory agreement signed

## Summary
- J. Scott Wolchko retired as President, CEO, and CFO effective Dec 31, 2024; resignation not due to any policy disagreement.
- Bahram Valamehr, Ph.D., MBA succeeded as President, CEO, and subsidiary roles effective Jan 1, 2025.
- Wolchko entered 12-month advisory agreement with $56,250 monthly cash compensation and continued equity vesting through Dec 31, 2025.
- Wolchko's vested options may be exercised until Dec 31, 2026; equity awards accelerate if agreement terminated early by company.

## SEC filing metadata
- accession: 0001193125-25-002153
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/0001193125-25-002153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/d900848d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-002153
- JSON: https://secwatch.observer/filing/0001193125-25-002153.json
- Plain text: https://secwatch.observer/filing/0001193125-25-002153.txt

## Key facts
- Executive change
  Bahram Valamehr was appointed as President and Chief Executive Officer at FATE THERAPEUTICS INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Bahram Valamehr, Ph.D., MBA has succeeded Mr. Wolchko in each of the Subsidiary Roles, effective as of January 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/0001193125-25-002153-index.htm
- Executive change
  J. Scott Wolchko retired as President, Chief Executive Officer, Chief Financial Officer at FATE THERAPEUTICS INC.
  - Action: retired
  - Role: President, Chief Executive Officer, Chief Financial Officer
  source text: J. Scott Wolchko retired from his positions as President, Chief Executive Officer (“CEO”), Chief Financial Officer, Treasurer, principal executive officer, principal financial officer and principal accounting officer of the Company, effective as of December 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/0001193125-25-002153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.